267 related articles for article (PubMed ID: 32053005)
21. Rifamycin action on RNA polymerase in antibiotic-tolerant
Saito K; Warrier T; Somersan-Karakaya S; Kaminski L; Mi J; Jiang X; Park S; Shigyo K; Gold B; Roberts J; Weber E; Jacobs WR; Nathan CF
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):E4832-E4840. PubMed ID: 28559332
[No Abstract] [Full Text] [Related]
22. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets.
Wellington S; Hung DT
ACS Infect Dis; 2018 May; 4(5):696-714. PubMed ID: 29412643
[TBL] [Abstract][Full Text] [Related]
23. Phosphoenolpyruvate depletion mediates both growth arrest and drug tolerance of
Lim J; Lee JJ; Lee SK; Kim S; Eum SY; Eoh H
Proc Natl Acad Sci U S A; 2021 Aug; 118(35):. PubMed ID: 34426499
[No Abstract] [Full Text] [Related]
24. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Saharan VD; Mahajan SS
Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
[TBL] [Abstract][Full Text] [Related]
25. A Multistress Model for High Throughput Screening Against Nonreplicating Mycobacterium tuberculosis.
Gold B; Warrier T; Nathan C
Methods Mol Biol; 2021; 2314():611-635. PubMed ID: 34235673
[TBL] [Abstract][Full Text] [Related]
26. Mycobacterium tuberculosis-secreted phosphatases: from pathogenesis to targets for TB drug development.
Wong D; Chao JD; Av-Gay Y
Trends Microbiol; 2013 Feb; 21(2):100-9. PubMed ID: 23084287
[TBL] [Abstract][Full Text] [Related]
27. TB drug development: immunology at the table.
Nathan C; Barry CE
Immunol Rev; 2015 Mar; 264(1):308-18. PubMed ID: 25703568
[TBL] [Abstract][Full Text] [Related]
28. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
[TBL] [Abstract][Full Text] [Related]
29. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity.
Lin Y; Zhang H; Zhu N; Wang X; Han Y; Chen M; Jiang J; Si S
Tuberculosis (Edinb); 2018 May; 110():79-85. PubMed ID: 29779778
[TBL] [Abstract][Full Text] [Related]
30. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
31. Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis.
Knudson SE; Cummings JE; Bommineni GR; Pan P; Tonge PJ; Slayden RA
Tuberculosis (Edinb); 2016 Dec; 101():8-14. PubMed ID: 27865404
[TBL] [Abstract][Full Text] [Related]
32. Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis.
John SF; Aniemeke E; Ha NP; Chong CR; Gu P; Zhou J; Zhang Y; Graviss EA; Liu JO; Olaleye OA
Tuberculosis (Edinb); 2016 Dec; 101S():S73-S77. PubMed ID: 27856197
[TBL] [Abstract][Full Text] [Related]
33. Novel targets in M. tuberculosis: search for new drugs.
Lamichhane G
Trends Mol Med; 2011 Jan; 17(1):25-33. PubMed ID: 21071272
[TBL] [Abstract][Full Text] [Related]
34. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.
Chuang YM; Dutta NK; Gordy JT; Campodónico VL; Pinn ML; Markham RB; Hung CF; Karakousis PC
Front Immunol; 2020; 11():680. PubMed ID: 32411131
[TBL] [Abstract][Full Text] [Related]
35. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
[TBL] [Abstract][Full Text] [Related]
36. Mycobacterial tuberculosis Enzyme Targets and their Inhibitors.
Saxena AK; Singh A
Curr Top Med Chem; 2019; 19(5):337-355. PubMed ID: 30806318
[TBL] [Abstract][Full Text] [Related]
37. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
[TBL] [Abstract][Full Text] [Related]
38. Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection.
Quan Y; Xiong L; Chen J; Zhang HY
J Biomol Struct Dyn; 2017 Feb; 35(3):616-621. PubMed ID: 26900080
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.
Lilienkampf A; Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP
J Med Chem; 2009 Apr; 52(7):2109-18. PubMed ID: 19271749
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.
Siricilla S; Mitachi K; Wan B; Franzblau SG; Kurosu M
J Antibiot (Tokyo); 2015 Apr; 68(4):271-8. PubMed ID: 25269459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
